Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT02139163
Recruiting Observational

Epidemiological Study on Community Acquired Pneumonia

NCT02139163 · tracked via the Priya Life Science Germany tracker
Sponsor
Capnetz Stiftung
Phase
Observational
Started
2002-10
Last updated
2026-05-05

Condition(s) studied

Community Acquired Pneumonia

Study summary

The main objective of this study is to investigate prevalence and risk factors for community-acquired pneumonia (CAP) and its interaction with comorbidities in an unselected group of adult patients receiving outpatient and inpatient care. In addition, information on HIV as a risk factor for CAP and on CAP in immunocompromised patients is collected.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * age ≥ 18 * infiltrate on chest X-ray * further Inclusion criteria (at least one must apply): cough or purulent sputum or pathologic lung auscultation (crackles) or fever Exclusion Criteria: * Hospitalization lasting longer than 48 hours prior to the diagnosis of the current pneumonia * Newly diagnosed, active pulmonary tuberculosis within the last 2 months

Primary outcome measure(s)

  • diagnosis — 2 weeks
    Assessment of diagnosis: Patients will be asked for example, about their diagnosis, comorbidities, specific risk factors and pneumonia symptoms.
  • therapy — 2 weeks
    Assessment of therapy: Patients will be asked about their therapy due to pneumonia symptoms, previous therapy, medication History etc.
  • hospitalization — 2 weeks
    Assessment of hospitalization: Patients will be asked about hospitalization, date, time and duration of hospitalization due to pneumonia symptoms.

Trial sites (1)

FacilityCityRegionStatus
Medical School Hannover Hanover Germany Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02139163 on ClinicalTrials.gov ↗ ← All trials in Germany